Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | CASP6 | P55212 | 1/20 | 0.64 |
| ▸ | GFER | P55789 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.55 |
| ▸ | CYP21A2 | P08686 | 3/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | CHKA | P35790 | 1/20 | 0.53 |
| ▸ | CCNC | P24863 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3096735 | 0.85 | CYP2C9 (1.00) | CYP2C9TSHRMEN1KMT2ACYP3A4 | |
| SCHEMBL4715494 | 0.85 | CHKA (0.57) | CYP2C9TSHRCASP6GFERMEN1 | |
| SCHEMBL16599286 | 0.85 | AKR1C3 (0.58) | CYP2C9TSHRCYP3A4SMN1; SMN2AKR1C3 | |
| SCHEMBL3404750 | 0.83 | SMN1; SMN2 (0.57) | CYP2C9TSHRMEN1KMT2ACYP3A4 | |
| SCHEMBL1283460 | 0.81 | SMN1; SMN2 (0.55) | CYP2C9TSHRCYP3A4SMN1; SMN2AKR1C3 | |
| SCHEMBL14344824 | 0.81 | CHKA (0.53) | CYP2C9TSHRCASP6GFERMEN1 | |
| SCHEMBL4670098 | 0.81 | USP2 (0.72) | CYP2C9TSHRCASP6GFERMEN1 | |
| SCHEMBL19002608 | 0.81 | CYP2C9 (0.51) | CYP2C9TSHRMEN1KMT2AMAPT | |
| SCHEMBL38663059 | 0.81 | HIF1A (0.76) | CYP2C9TSHRMEN1KMT2AMAPT | |
| SCHEMBL8838124 | 0.81 | TRPV1 (0.61) | CYP2C9TSHRCYP3A4SMN1; SMN2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3642209-B1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY Therapeutics LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-3394056-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2017112777-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
| US-20100324284-A1 | PYRROLOPYRIMIDINE DERIVATIVE AS P13K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2010-12-23 | — | — | US | disclosed |
| US-20100324284-A1 | PYRROLOPYRIMIDINE DERIVATIVE AS P13K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2010-12-23 | — | — | US | disclosed |
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| EP-2108642-A1 | JAK INHIBITOR | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-10-14 | — | — | EP | disclosed |
| WO-2009099163-A1 | PYRROLOPYRIMIDIN DERIVATIVE FOR USE AS PI3K INHIBITOR, AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-08-13 | — | — | WO | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| EP-1880993-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-01-23 | — | — | EP | disclosed |
| EP-1421071-A2 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | NOVO NORDISK A/S (DK) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003004480-A2 | SUBSTITUTED PIPERAZINE AND DIAZEPANES AS HISTAMINE H3 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | NR4A1, NR5A2, PRMT8 | CYP2C9 342/4885TSHR 563/4885CASP6 4460/4885 |
| US-20100324284-A1 | PYRROLOPYRIMIDINE DERIVATIVE AS P13K INHIBITOR AND USE THEREOF | CSNK1A1, CSK, CSNK1A1L | CYP2C9 2375/4885TSHR 3447/4885CASP6 1164/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | CYP2C9 4774/4885TSHR 4461/4885CASP6 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.